Quick Answer
Biodexa Pharmaceuticals Plc reported Total Assets of $18.18 million for fiscal year 2025.
Biodexa Pharmaceuticals Plc — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Assets | $18.18M +23.0% |
$14.78M +40.2% |
$10.54M +90.8% |
$5.53M -57.2% |
$12.91M +31.5% |
$9.82M -68.2% |
| R&D Expense | $3.96M -27.1% |
$5.44M +33.7% |
$4.07M -20.4% |
$5.11M +9.8% |
$4.65M -23.3% |
$6.07M -22.6% |
| Gross Profit | — | — | — | — | — | — |
- Biodexa Pharmaceuticals Plc reported Total Assets of $18.18 million for fiscal year 2025.
- Biodexa Pharmaceuticals Plc showed an increase of +23.0% in Total Assets compared to the prior fiscal year.
- Biodexa Pharmaceuticals Plc reported R&D Expense of $3.96 million for fiscal year 2025.
- Biodexa Pharmaceuticals Plc showed a decrease of -27.1% in R&D Expense compared to the prior fiscal year.
- Biodexa Pharmaceuticals Plc reported Gross Profit of $6.67 million for fiscal year 2017.
- Biodexa Pharmaceuticals Plc showed an increase of +6.6% in Gross Profit compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: